NCT06218524View on ClinicalTrials.gov

The Effectiveness of HP and TMZ Synergism on Adult Recurrence GBM

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

July 31, 2028

Conditions
Glioblastoma Multiforme
Interventions
DRUG

Haloperidol Tablets

Haloperidol tablet 6mg, Oral, Triple/Day

DRUG

Temozolomide

Temozolomide, 150mg/kg, Oral, Once/Day, 5/28 days

All Listed Sponsors
lead

Southern Medical University, China

OTHER

NCT06218524 - The Effectiveness of HP and TMZ Synergism on Adult Recurrence GBM | Biotech Hunter | Biotech Hunter